Cholestor Indications/Uses

Dyslipidemias: Rosuvastatin is used as an adjunct to dietary therapy in the management of primary hypercholesterolemia and mixed dyslipidemia. Rosuvastatin is also used in the management of hypertriglyceridemia. The efficacy of rosuvastatin in patients with Frederickson type I, III, or V dyslipidemia has not been established. Nondrug therapies and measures specific for the type of hyperlipoproteinemia (therapeutic lifestyle changes) are the initial treatments of choice, including dietary management (e.g., restriction of saturated fat and cholesterol intake, addition of plant stanol/sterols and viscous fiber to diet), weight control, an appropriate program of physical activity, and management of potentially contributory disease. Drug therapy is not a substitute for but an adjunct to these nondrug therapies and measures, which should be continued when drug therapy is initiated.
Primary Hypercholesterolemia and Mixed Dyslipidemia: Rosuvastatin is used as an adjunct to dietary therapy to reduce elevated total cholesterol, LDL-cholesterol, apolipoprotein B (apo B), non-high-density (non-HDL)-cholesterol, and triglyceride concentrations and to increase HDL-cholesterol in patients with primary hypercholesterolemia (heterozygous familial and nonfamilial) and mixed dyslipidemia. Rosuvastatin alone or combined with extended-release niacin improves the atherogenic lipid profile in patients with mixed dyslipidemia and low HDL-cholesterol concentrations.
Homozygous Familial Hypercholesterolemia: Rosuvastatin also is used to reduce elevated serum total cholesterol and LDL-cholesterol and apo B concentrations in patients with homozygous familial hypercholesterolemia, as an adjunct to other lipid-lowering therapies (e.g., plasma LDL-apheresis) or if such treatments are unavailable.
Hypertriglyceridemia: Rosuvastatin is used as an adjunct to diet in the treatment of patients with elevated triglyceride concentrations (Fredrickson type IV).
Prevention of cardiovascular events: In adult patients with an increased risk of atherosclerotic cardiovascular disease based on the presence of cardiovascular disease risk markers such as an elevated high sensitivity C-reactive protein (hsCRP) level, age, hypertension, low HDL-Cholesterol, smoking or family history of premature coronary heart disease, Rosuvastatin is indicated to reduce total mortality and the risk of major cardiovascular events (cardiovascular death, stroke, myocardial infarction, unstable angina, or arterial revas-cularization).